Coloplast stock heads for November 3, 2026 annual results

Published on 10/15/2026 at 21:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays kept a DKK 465.00 target on October 5, 2026. Coloplast stock costs EUR 62.62 on October 15, 2026 at 9:03 p.m. CEST.

Calendar and valuation details

Annual results are scheduled for November 3, 2026.
Barclays maintained a Hold rating and a DKK 465.00 target on October 5, 2026.
Coloplast stock costs EUR 62.62 at Lang & Schwarz on October 15, 2026 at 9:03 p.m. CEST.
Coloplast had a trailing P/E ratio of 34.12 on October 14, 2026.

Geometrisches Bauhaus-Poster in Blau, Weiß und Terrakotta mit dem Wort Medtech — Coloplast A/S (DK0060448595) als Medizintechnik-Unternehmen inspiriert dieses geometrische Bauhaus-Poster mit dem Sektor-Schriftzug Medtech, Illustration mit AI erstellt.

Coloplast is scheduled to publish its annual results on November 3, 2026, according to MFN. The date gives investors the next fixed point for assessing growth, margins and the company's full-year performance. Coloplast stock was priced at EUR 62.62 at Lang & Schwarz on October 15, 2026 at 9:03 p.m. CEST.

November 3 date is next

The November 3 publication is the next scheduled annual results event in Coloplast's financial calendar. The calendar also lists the next annual meeting for December 1, 2026, giving shareholders a second dated event after the results release, according to MFN.

Barclays target stays at DKK 465.00

Barclays analyst Hassan Al-Wakeel maintained a Hold rating and set a DKK 465.00 price target on October 5, 2026, as reported by The Globe and Mail. The target is stated in Danish kroner and therefore is not combined with the euro quotation. The same report described a DKK 465.00 average consensus target.

Price and yearly range

The Lang & Schwarz quote stood at EUR 62.62 in after-hours trading on October 15, 2026 at 9:03 p.m. CEST. The same euro quotation had a 52-week range of EUR 49.72 to EUR 82.96 as of October 14, 2026, placing the price EUR 13.24 above the low and EUR 20.34 below the high. Coloplast's year-to-date performance was 8.37 percent as of October 14, 2026.

Valuation and calendar

Coloplast carried a market capitalization of EUR 13.7 billion and a trailing P/E ratio of 34.12 as of October 14, 2026. Its dividend yield was 5.45 percent on the same date. The valuation figures provide a numerical frame for the November 3 results, when the market can compare the full-year outcome with expectations.

Comparison with peers

Coloplast: P/E 34.12, market capitalization EUR 13.7 billion.

ConvaTec (LSE, GBp): plus 0.94 percent, P/E 50.36, market capitalization GBP 4.5 billion.

Smith & Nephew (LSE, GBp): plus 3.62 percent, P/E 19.51, market capitalization GBP 9.1 billion.

Stock price after hours

The euro quotation gives German investors a current trading marker, while the November 3 date remains the next company-specific checkpoint. Coloplast is listed on Nasdaq Copenhagen and operates in medical instruments and supplies, with products spanning ostomy care, continence care, wound care and urology.

The further course of trading is shown by the continuously updated real-time quote of Coloplast stock.